


Available online on 15.05.2020 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited



Open Access

Review Article

Management of Hypertension with Conventional and Herbals Drugs

Marjina¹, Amandeep Singh^{1,3}, Amit Sharma², Raj Kumar Narang¹, Gurmeet Singh^{1*}¹Department of Pharmaceutics, ISF College of Pharmacy, Moga-142001, Punjab, India²Department of Pharmacy practice, ISF College of Pharmacy, Moga-142001, Punjab, India³Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda- 151001, Punjab, India

ABSTRACT

In this article, we have discussed about Types (primary, secondary, isolated, white coat, malignant, resistant and pulmonary hypertension), classification, adverse drug reactions of antihypertensive drugs (beta-blocker induce psoriasis and calcium channel blocker cause peripheral oedema. ACE inhibitor produce ankle oedema and thiazide diuretics causes hyponatremia and also hyperglycaemia. These are some of the serious adverse drug reactions associated with patients who are being treated with these drugs), measurement, management, diagnosis and associated diseases (e.g. diabetes mellitus, heart disease, cerebrovascular disease) lastly concluded about the herbal approach for management of hypertension .

Keywords: Hypertension, conventional drugs, Herbal drugs

Article Info: Received 11 March 2020; Review Completed 22 April 2020; Accepted 29 April 2020; Available online 15 May 2020



Cite this article as:

Marjina, Singh A, Sharma A, Narang RK, Singh G, Management of Hypertension with Conventional and Herbals Drugs, Journal of Drug Delivery and Therapeutics. 2020; 10(3):280-287 <http://dx.doi.org/10.22270/jddt.v10i3.3998>

*Address for Correspondence:

Mr Gurmeet Singh, Assistant Professor, Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India Postal Code: 142001.

1. INTRODUCTION

Persistent elevation in blood pressure is known as hypertension. In hypertension, systolic blood pressure (SBP) is greater than 140 mmHg or diastolic blood pressure (DBP) is greater than 90 mmHg.¹⁴

Table 1: Categories/stages of hypertension: (14)

Category	SBP	DBP
Normal	<120	<80
Pre-hypertension	120-139	80-89
Stage-1	140-159	90-99
Stage-2	>160	>100

Blood pressure (BP) = cardiac output (CO) × peripheral vascular resistance

Cardiac output (CO) = heart rate (H.R.) × stroke volume (SV)

Heart rate: number of beats per minute (72).

Stroke volume: The amount of blood pumped in 1 heart beat (60ml).

1.1 Epidemiology

Hypertension is public health problem in both developing and developed countries and affecting about 20% adult population shown in figure 1. Worldwide, 7.5 million premature deaths (about 13.5% of the global total) were due to hypertension. About 55% of stroke and 48% of ischaemic heart diseases worldwide attributable to high blood pressure. Prevalence of hypertension in India is about 27% in men and 24% in women. According to statistics cases of hypertension increased 10 times in last 4 decades in rural India and almost 30 times in urban India ¹.




Fig. 1 Negative impact of hypertension

1.2 Symptoms

Hypertension has no sign and symptoms. Therefore, it is also called as “**silent killer**”. A small amount of people may experience symptoms such as:

- Severe Headache
- Vomiting
- Nosebleeds
- Fatigue
- Chest pain
- Blurred vision

But, these symptoms usually do not occur until blood pressure level reaches to life threatening stage ².

1.3 Causes of Hypertension

- Hereditary
- Obesity
- High sodium intake
- Psychological stress
- stress

Other factors also play a role:

- Excessive alcohol drinking
- Smoking
- Physical inactivity ³.

2. TYPES OF HYPERTENSION

2.1 Primary hypertension/essential hypertension (95 to 96%): it has no clear cause. But, frequent headache and tiredness is common.

2.2 Secondary hypertension (4 to 5%): in secondary hypertension cause can be found and it includes:

- Hormonal abnormalities
- Too much salt in the diet
- Alcohol consumption
- Drugs can also cause secondary hypertension

Example: over the counter drug (OTC), ibuprofen, Pseudoephedrine.

If the cause is found, hypertension (HTN) can often be controlled ⁴.

3. OTHER TYPES OF HYPERTENSION

3.1 Isolated systolic hypertension: in this, systolic blood pressure tends to rise above 140 and diastolic blood pressure tends to fall and most common in people over the age 65.

3.2 White coat hypertension: this term is used to denote individuals who have normal BP outside doctor’s office but, high BP in the medical environment therefore, the patients with this type of hypertension feel extremely stressed when they visit doctor’s office.

3.3 Malignant hypertension: occur only in 1% of people with hypertension and in this DBP goes over 130, treated only in hospital.

3.4 Resistant hypertension: if three different types of medications are prescribed by the doctor but, blood pressure is still too high. Then it is called resistant hypertension ⁵.

3.5 Pulmonary hypertension: pulmonary hypertension means high blood pressure in the arteries going to lung. In healthy individuals, the BP in these arteries is much lower than in the rest of the body.

Pulmonary arterial BP is about 25/10mmHg in healthy individuals. If this pressure exceeds 40/20 mmHg it means pulmonary hypertension is present ⁶.

4. CLASSIFICATION OF ANTI-HYPERTENSIVE DRUGS

4.1 Diuretics

Diuretics such as hydrochlorothiazide lower BP by increasing sodium and water excretion or urination. This cause a decrease in cardiac output and peripheral resistance and ultimately blood pressure decreases. Examples are Bumetanide, Furosemide, Hydrochlorothiazide, Spironolactone, Triamterene ¹⁴.

4.2 Beta-blockers

The β -blockers reduce blood pressure by decreasing cardiac output and also inhibit the release of rennin from the kidneys, thus decreasing the formation of angiotensin-2 and the secretion of aldosterone therefore volume of blood decreases which leads to decrease in BP. Examples are Atenolol, Propranolol, Labetolol, Timolol ¹⁴.

4.3 ACE inhibitors

These drug blocks the ACE that convert angiotensin-1 into angiotensin-2. Thus, ACE inhibitors decrease angiotensin-2 level so, reduce constriction and also secretion of aldosterone that control the level of sodium and water ions. Hence, B.P. decreases. Examples are Captopril, Enalapril, Lisinopril, Quinapril, Ramipril ¹⁴.

4.4 Angiotensin2-receptor antagonist (ARB)

Angiotensin receptor blocker alternative to the ACE inhibitors. These drugs blocks the AT1 receptors, result in vasodilatation and also block aldosterone secretion. Examples are Candesartan, Irbesartan, Losartan, Telmisartan, Valsartan ¹⁴.

4.5 Renin inhibitors

Aliskiren directly inhibit rennin and thus, acts earlier in the rennin angiotensin aldosterone system than ACE inhibitors or ARBs. It decrease blood pressure about as effectively as ARBs, ACE inhibitors and thiazides. For example Aliskiren. But, aliskiren cause diarrhea at higher doses ¹⁴.

4.6 Calcium channel blockers

Calcium is responsible for contraction and the calcium channel antagonist block the inward movement of calcium by binding to L-type calcium channels in the heart, these cause vascular smooth muscles to relax or channel blockers lower B.P by reducing myocardial contractility. For example, Amlodipinem, Diltiazem, Felodipine, Nicardipine, Nifedipine, Verapamil ¹⁴.

4.7 Alpha-blockers

Alpha blockers block the α 1 receptor. They decrease peripheral vascular resistance and lower arterial blood pressure by causing relaxation of both arterial and venous smooth muscles because these receptors are present on vascular smooth muscle. For example Prazosin, Doxazosin ¹⁴.

4.8 Other

Sodium nitroprusside: nitroprusside is administered intravenously and cause prompt vasodilation. It is capable of reducing BP in all the patients.but, nitroprusside is metabolized quickly and requires continuous infusion for the maintainance of its hypotensive action. For example Hydralazine(vasodilator) ¹⁴.

Table 2: Commonly used antihypertensive drugs: ⁷.

S.NO.	CLASS	GENERIC NAME	DOSE(mg)	BRAND NAME
1.	Diuretics	Hydrochlorothiazide Indapamide furosemide	12.5-50 1.25-5 200-400	Hydrex Natrilex Lasix
2.	Beta-blocker	Atenolol Metoprolol	25-100 50-200	Blockium Betaloc
3.	Calcium antagonist	Verapamil Diltiazem	120-480 90-240	Tarka isoptin retard Tildium altiazem
4.	ACE inhibitors	Captopril Enalapril Lisinopril	50-150 2.5-40 10-40	Capozide Ezapril Zestril
5.	ARB	Losartan Valsartan Candesartan	25-100 80-320 4-32	Fortzar Co-diovan Atacand
6.	Alpha-blocker	Prazosin Doxazosin	1-16 1-16	Minipress Cardura
7.	Centrally acting drugs	Methyl dopa Clonidine	500-2000 0.1-1.2	Aldomet Catapres

5. ADVERSE EFFECTS OF ANTI HYPERTENSIVE DRUGS

5.1 Hypokalemia

Diuretics cause hypokalemia and it is treated by rational medication combination. Low dose thiazide combined with ACE or ARBs to maintain the potassium concentration sufficiently.

5.2 Hyponatremia

One of the most common problems with thiazide diuretics is hyponatremia. Those who develop hyponatremia should be changed to other class of drugs. If still diuretics are required a low dose of long acting loop diuretics (e.g. torsemide 2.5-5mg daily) is effective.

5.3 Edema

Antihypertensive medication induced edema is more common. Women may be particularly susceptible to calcium channel blocker induced edema. But, peripheral edema can be minimized by decreasing the dose.

5.4 Erectile dysfunction

It affects about 30% of men with hypertension. Both hypertension and erectile dysfunction are disorders of endothelial dysfunction. Preliminary evidence suggests that combination of phosphodiesterase type-5 inhibitors (PDE5) and alpha-blockers improve erectile dysfunction⁸.

5.5 Psoriasis

The use of beta-blocker may result in psoriasis and if we substitute any other beta-blocker it may further cause skin lesions. If psoriasis is present only in localized area then, emollients can be helpful.

5.6 Hyperglycaemia

Hyperglycaemia is more common and severe adverse effect is seen with thiazide diuretics than other class of anti-hypertensive drugs. Patient with diuretic induced hyperglycaemia are often considered as having type-2 diabetes and are prescribed with oral anti-diabetic agent⁹.

6. B.P. MEASUREMENT

6.1 Sphygmomanometer

The sphygmomanometer was invented by **Samuel Siegfried Karl Ritter Von Basch** in the year 1881. Sphygmomanometer self-measurement of blood pressure device.

6.2 Points to be considered during the measurement of B.P.¹⁰.

6.2.1 Posture of patient

Allow the patient to be seated for few minutes before the measurement of blood pressure. B.P. should be measured when the patient in a relaxed state, the arm at the level of heart and the legs are not crossed.

6.2.2 B.P. device

The device should be validated.

6.2.3 Cuff size

The cuff with bladder whose length is at least 80% of the arm circumference is preferable.

6.2.4 Number of measurements

At least two readings should be taken at each visit with an interval of at least 1 min. this will avoid the calculation error involved in averaging the two measurements. Due to variability of B.P. measurements the diagnosis of hypertension should be made only after multiple readings.

Table 3:

S.NO.	Measurement error	Effect on B.P.
1.	Back is not supported	Diastolic blood pressure increased by 6mmHg
2.	Legs are crossed	Systolic B.P. increased by 2-8mmHg
3.	Arm is not at the level of heart	Increase B.P. by 10-12mmHg

7. MANAGEMENT OF HYPERTENSION¹¹.

Non pharmacological management plays an important role for the improvement of overall cardiovascular diseases. It include:

7.1 Weight reduction: Dietary interventions to lower body weight also recommended for people with hypertension. Weight reducing diet reduces about 4.5/3.2mmHg blood pressure.

7.2 Sodium intake: Reduce sodium intake sufficiently reduces B.P. in adults. A recent study has shown that reduction of sodium intake from 11.6g of salt to 3.8g of salt decrease the B.P. in asian people.

7.3 Alcohol consumption: Alcohol consumption increases B.P. reducing alcohol intake reduce B.P. by 3.3/2mmHg. People who drink are advised to limit the consumption of alcohol.

7.4 Regular physical activity: Increased physical activity has been shown to reduce blood pressure. Aerobic exercise of at least 150 min. per week is beneficial.

7.5 Healthy eating: A diet rich in fruits, vegetables, low fat dairy products can lower B.P. DASH (dietary approaches to stop hypertension) diet significantly lower the B.P. and it include, Grains, Vegetables, Fruits, Low fat dairy foods, Nut, seeds, beans.

7.6 Cessation of smoking: Smoking cessation is important in reducing global cardiovascular risk.

7.7 Dietary potassium intake: Increase dietary potassium intake reduces B.P. in adults without adverse effect on blood lipid concentration. Dietary potassium can reduce B.P. by 3.49/1.96mmHg and also lower the risk of stroke by 25% this can be achieved by eating fruits, vegetables, nuts and legumes.

8. ASSOCIATED DISEASES WITH HYPERTENSION

8.1 Diabetes mellitus

Patient with diabetes mellitus should be initiated on drug therapy when the SBP is greater than 140mmHg. ACE inhibitors are used initially than calcium channel blockers and diuretics used as add on therapy.

8.2 Heart disease

Beta-blockers used in patient with hypertension and a recent myocardial infarction. In case of angina, beta-blockers and calcium channel blockers are prefer but, in patient with heart failure and hypertension thiazide diuretics are more preferable.

8.3 Cerebrovascular disease

Initiation of drug treatment should be considered with grade 1 hypertension in patient with stroke history. Do not administer antihypertensive drugs in first 72 hours of ischemic stroke¹².

9. DIAGNOSIS OF HYPERTENSION:

- 9.1 Measure B.P. in both the arms for the diagnosis of hypertension
- 9.1.1 Repeat the measurements, if the difference in readings between arms is more than 15mmHg.
- 9.1.2 Measure subsequent B.P. in the arm if the difference between the arms more than 15mmHg on the second measurement.
- 9.2 When B.P. measurement is inside the clinic 140/90mmHg or higher
- 9.2.1 During the consultation take second measurement.
- 9.2.2 Take third measurement if second is different from first
- 9.3 Ambulatory blood pressure monitoring (ABPM) – if clinic blood pressure is between 140/90 and 180/120mmHg to confirm the diagnosis of hypertension.
- 9.4 If ABPM is unsuitable for the person offer home blood pressure monitoring (HBPM) for the diagnosis of hypertension.
- 9.5 When using ABPM ensure that at least 2 measurements taken per hour during the person's waking hour (e.g. between 8.00 and 22.00). When using HBPM ensure that for each blood pressure recording, 2 consecutive measurements are taken¹³.

Patient presentation	Patient presents with uncontrolled BP (>140/90)
Check clinic blood pressure	Controlled clinic blood pressure measurement: Take a first measurement. Take a second measurement, if BP is high. If the last measurement is different from the first, take a third measurement. The last two measurements recorded as a clinic BP.
Rule out white coat hypertension	Refer for ambulatory BP monitoring, if blood pressure is uncontrolled.
Rule out non-adherence to medication	If BP is uncontrolled on ABPM consider: Urine analysis Directly observed dosing
Diagnosis	Diagnosis of resistant hypertension can be made if BP is uncontrolled.

10. NOVEL DRUG DELIVERY SYSTEM FOR HYPERTENSION

S. N.	Drug	Delivery system/formulation approaches	Applications
1.	Perindopril	Mucosal administration route ODT: orodispersible tablets perindopril arginine	Treatment of hypertension/heart failure ¹⁵ .
2.	Nitrendipine	Sublingual mucosal route	Effectively reduce B.P during first 45 min ¹⁵ .
3.	Amlodipine	Transmucosal administration	Effective in coronary heart disease and hypertension ¹⁵ .
4.	Metoprolol	Rectal administration of metoprolol tartrate	Reduce B.P. significantly faster without severe side-effects ¹⁵ .
5.	Propranolol	Rectal administration and Sublingual administration	Sustain release of drug ¹⁵ .
6.	Carvedilol	Solid lipid nanoparticles(SLN) And nanosuspensions	Enhance bioavailability and protecting it from acidic environment ¹⁶ .
7.	Candesartan cilexetil	Dendrimers and Nanosuspensions	Improved water solubility ¹⁶ .
8.	Nifedipine	Polymeric nanoparticles and Dendrimers	Increase dissolution rate ¹⁶ .
9.	Felodipine	Nanosuspensions/ Polymeric nanoparticles	Control the release of drug ¹⁶ .
10.	Valsartan	Proliposomes and self non-emulsifying drug delivery system	*Bypass first pass metabolism *Prolong release of drug ¹⁶ .
11.	Nebivolol	Polymeric nanoparticles	Prolonged drug release ¹⁶ .
12.	Isradipine	Transdermal penetration of drug	Management of hypertension ¹⁷ .
13.	Olmесartan	Nano-invasomes formulation/Transdermal delivery system(TDDS)	Increase bioavailability ¹⁷ .
14.	Bosentan	Nanoparticles endothelin receptor antagonist	Effective in pulmonary hypertension ¹⁸ .
15.	Aliskiren	Poly(D,L-lactide)(PLA) Oral gavage	Prevent stroke by lowering high B.P ¹⁸ .
16.	Lacidipine	Niosomes	Helps to relax blood vessels ¹⁸ .

17.	Captopril	Chitosan polymer/oral route	Improve survival after a heart attack
18.	Sildenafil	Endotracheal administration	Treat pulmonary hypertension ¹⁸ .
19.	Tacrolimus(TAC)	Nanocompositae particles Endotracheal administration	Pulmonary hypertension
20.	Silaenafil	Poly (D,L-lactide-co-glycolide) nanoparticles Endotracheal administration	Pulmonary HTN ¹⁸ .
21.	Cerivastatin	Liposomes Endotracheal administration	Pulmonary HTN ¹⁸ .
22.	Lercanidipine	Proliposomes/ Oral dose using intragastric tube	Immediate and long lasting (24h) reduction in systolic blood pressure ¹⁹ .
23.	Super-oxide dismutase (SOD)	Lipose encapsulation/daily injections	Reduce mean arterial pressure (MAP) by 50mmHg ¹⁹ .
24.	Covera-HS;XL tablet	Osmotic control release oral drug delivery system(OROS)/ chronopharmaceuticals	Prevent the dangerous surge of B.P in the early morning ²⁰ .
25.	Verelan PM;XL release capsule	Chronotherapeutic oral drug absorption system(CODAS)	Manage hypertension in the morning ²⁰ .
26.	Innopran ;XL tablets	DIFFU CAS multiparticulate bead system comprised of multiple layers of drug, excipients and release controlling polymers	Release is pH independent ²⁰ .
27.	Pulsincap	PULSINCAP rupturable system	Release is pH independent ²⁰ .
28.	Procardia XL	PROCARDIA XL sustained release tablet	Decrease the frequency of chest pain attacks ²⁰ .
29.	Cardizem LA;	CEFORM extended release tablet	Production of uniformly sized and shaped microsphere ²⁰ .
30.	ramipril	Polymeric nanoparticles/chitosan	Used to treat high B.P and congestive heart failure (CHF) ²⁰ .
31.	Nisoldipine	Solid lipid nanoparticles	Lower high blood pressure ²¹ .
32.	Eplerenone (ARB)	Oral route	Treat high blood pressure ²¹ .
33.	Taladafil (phosphodiesterase-5-inhibitor)	Oral route	Effective in pulmonary hypertension ²¹ .
34.	Imidapril (ACE) inhibitors	By mouth	Manage high blood pressure ²¹ .
35.	Azilsartan (angiotensin-1 receptor blocker)	Orally/40mg or 80mg	Treat hypertension ²¹ .
36.	Macitentan (endothelin A receptor blocker)	Orally/10mg	Pulmonary hypertension ²¹ .
37.	Ambrisentan EARB(endothelinA receptor blocker)	Film coated tablet/orally	Pulmonary HTN ²¹ .
38.	Monoxidine(imidazolidine receptor blocker)	Oral route	Treat mild to moderate essential hypertension ²¹ .
39.	Cicletanine (endothelila nitric oxide synthase coupler)	Orally	It's a diuretic drug for the treatment of hypertension ²¹ .

11. NOVEL BRANDED DRUGS FOR THE TREATMENT OF HYPERTENSION

S. No	Drug	Delivery system/formulation approaches	Applications
1	Flolan (prostacyclin derivative)	Intravenous(I.V)	Treatment of pulmonary arterial hypertension (PAH) ²² .
2	Velettri (prostacyclin derivative)	I.V	Treatment of PAH ²² .
3	Ventavis (prostacyclin derivative)	Inhaled	Treatment of PAH ²² .
4	Remodulin (prostacyclin derivative)	Subcutaneous (SC)/IV	Treatment of PAH ²² .
5	Tyvaso (prostacyclin derivative)	Inhaled	Treatment of PAH ²² .
6	Tracleer (endothelin receptor antagonist/ERA)	Oral	Treatment of PAH ²² .
7	Letairis (ERA)	Oral	Treatment of PAH ²² .
8	Revatio (PDE-5-inhibitor)	Oral	Treatment of PAH ²² .
9	Adcirca (PDE-5-inhibitor)	Oral	Treatment of PAH ²² .

12. NEW COMBINATION THERAPY

S. No	Drug	Delivery system/ formulation approaches	Applications
1	Sildenafil + Epoprostenol	Oral /IV	Treatment of PAH ²² .
2	Iloprost + Bosentan	Inhaled /oral	For the treatment of idiopathic pulmonary arterial hypertension (IPAH) ²² .

13. HERBAL DRUGS AS BOOM FOR THE MANAGEMENT OF HYPERTENSION:

- The use of herbal medicines throughout the world exceeds as compare to conventional drugs by two to three times.
- It is the oldest form of health care for the prevention and treatment of illness.
- Herbal drugs are phytochemical compounds used for the treatment of many diseases such as hypertension because herb has active ingredients which act as drug.
- Herbal drugs are less expensive than synthetic drugs and people in the rural area mostly used these drugs due to less side effects²³.

- Herbal drugs also have different pharmacokinetic and pharmacodynamic properties which leads to therapeutic responses.

13.1 Advantages of Herbal Medicines:

- Easily available.
- Safe and effective.
- Environmental friendly.
- Patient compliant.
- Fewer side effects as compared to allopathic medicines.²⁴.

13.2. Herbal drugs which are used as antihypertensive agents:

S.No.	Drug (common name)	Botanical Name	Pharmacological class
1.	Lotus	Nelumbo nucifera	Vasodilator ²⁵ .
2.	Ginseng	Panax ginseng	Vasodilator ²⁵ .
3.	Garlic	Allium sativum	ACE inhibitors ²⁵ .
4.	Snake root	Rouwolfia serpentina	Vasodilator ²⁵ .
5.	Ginger	Gingiber officinalis	Vasodilator ²⁵ .
6.	Ginko	Ginko biloba	Vasodilator ²⁵ .
7.	Hawthorn	Crataegus oxycantha	Vasodilator ²⁵ .
8.	Punarnava	Boerhavia diffusa	Diuretic ²⁵ .
9.	Ashwagandha	Withania somnifera	Diuretic ²⁵ .
10.	Arjuna	Termenalia arjuna	Diuretic ²⁵ .
11.	Black cumin seeds	Nigella sativa	Centrally acting ²⁵ .
12.	Alpinia	Alpinia zerumbet	Diuretic ²⁵ .
13.	Raisins	Vitis vinifera	Vasodilator ²⁵ .
14.	Olive leaf	Olea europea	Vasodilator ²⁵ .
15.	Beetroot	Beta vulgaris	Nitrodilator ²⁵ .
16.	Tea	Camellia sinensis	Nitrodilator/diuretic ²⁶ .
17.	Saffron	Crocus sativus	Calcium channel blocker ²⁶ .
18.	Roselle	Hibiscus sabdariffa	Calcium channel blocker/vasodilator ²⁶ .
19.	King of bitter	Andrographis paniculata	Nitrodilar /ACE-inhibitor ²⁶ .
20.	Celery	Apium graveolens	Calcium channel blocker ²⁶ .

14. CONCLUSION

The use of combination therapy as first line treatment will help more patients. This review is associated with treatment, management, adverse effects of drugs and diagnosis mainly.

There is need for safe and effective therapies to achieve recommended blood pressure targets. This review article also provides help in the detection of B.P. and in the selection of particular antihypertensive drug with herbal drugs.

REFERENCES

1. Kishore J. Gupta N. Kohli C. Kumar N. Prevalence of hypertension and determination of its risk factors in rural Delhi. *International journal of hypertension*. 2016.
2. Bell K. Twiggs J. Bernie R. Hypertension: The Silent Killer: Updated JNC-8 Guideline. Harrison School of Pharmacy, Auburn University, *Alabama Pharmacy Association*. 2015.
3. Tain YL. Lin YJ. Sheen JM. Lin IC. Yu HR. Huang LT. Hsu CN. Resveratrol prevents the combined maternal plus postweaning high-fat-diets-induced hypertension in male offspring. *The Journal of nutritional biochemistry*. 2017; 1(48):120-7.
4. Joseph P. Leong D. McKee M. Anand SS. Schwalm JD. Teo K. Mente A. Yusuf S. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. *Circulation research*. 2017; 121(6):677-94.
5. Brown D. Edwards H. Seaton L. Buckley T. Lewis's Medical-surgical Nursing: Assessment and Management of Clinical Problems. *Elsevier Health Sciences*; 2017; 25.
6. Gredic M. Blanco I. Kovacs G. Helyes Z. Ferdinandy P. Olschewski H. Barberà JA. Weissmann N. *Pulmonary hypertension in chronic obstructive pulmonary*.
7. Izzo R. Patient with Essential Hypertension and Left Ventricular Enlargement. *InHypertension and Cardiac Organ Damage* 2017. 61-73.
8. Ripley TL. and Anna Barbato, Pharm. D., BCPS, AHSCP-CHC.
9. Sudhakar R. George MK. Yaraswini B. Sundararajan . Mariyam AS. Adverse drug reactions associated with anti-hypertensive drugs and its management. *International Journal of Pharmaceutical Sciences and Research*. 2016; 7(3):898.
10. O'Brien E. Asmar R. Beilin L. Imai Y. Mancia G. Mengden T. Myers M. Padfield P. Palatini P. Parati G. Pickering T. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. *Journal of hypertension*. 2005; 23(4):697-701.
11. Verma S. Chan LL. Chee KS. Chen H. Chin SA. Chong SA. Chua W. Fones C. Fung D. Khoo CL. Kwek SK. Corrigendum. Ministry of health clinical practice guidelines: *schizophrenia*.
12. Bathgate CJ. Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. *Current hypertension reports*. 2018; 20(6):52.
13. Siu AL. Screening for high blood pressure in adults: US Preventive Services Task Force recommendation statement. *Annals of internal medicine*. 2015; 163(10):778-86.
14. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. CG 127.
15. Bialy LP. Wojcik C. Mlynarczuk-Bialy I. Mucosal delivery systems of antihypertensive drugs: A practical approach in general practice. *Biomedical Papers*. 2018; 162(2):71-8.
16. Sharma M. Sharma R. Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. *Scientifica*. 2016.
17. Sharma M. Sharma R. Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. *Scientifica*. 2016; 2016.
18. Deng Y. Zhang X. Shen H. He Q. Wu Z. Liao W. Yuan M. Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases. *Frontiers in Bioengineering and Biotechnology*. 2019; 7.
19. Khan AR. Liu M. Khan MW. Zhai G. Progress in brain targeting drug delivery system by nasal route. *Journal of Controlled Release*. 2017; 268:364-89.
20. Neeharika MS. Jyothi BJ. Chronotherapeutics: an optimizing approach to synchronize drug delivery with circadian rhythm. *Journal of Critical Reviews*. 2015; 2(4):31-40.
21. Alam T. Khan S. Gaba B. Haider MF. Baboota S. Ali J. Nanocarriers as treatment modalities for hypertension. *Drug delivery*. 2017; 24(1):358-69.
22. Lewis RS. Deen WM. Kinetics of the reaction of nitric oxide with oxygen in aqueous solutions. *Chemical research in toxicology*. 1994; 7(4):568-74.
23. Nisar B. Sultan A. Rubab SL. Comparison of medicinally important natural products versus synthetic drugs-a short commentary. *Nat Prod Chem Res*. 2017; 6(308):2.
24. Koka JA. Bhat MY. Wani AH. Allelopathic effect of leaf extracts of *Punica granatum* and *Spiraea prunifolia* against post-harvest rot of tomato and brinjal. *Journal of Drug Delivery and Therapeutics*. 2020; 10(2-s):1-6.
25. Agrawal M. Nandini D. Sharma V. Chauhan NS. Herbal remedies for treatment of hypertension. *Int J Pharm Sci and Res*. 2010; 1(5):1-21.
26. Chrysant SG. Chrysant GS. Herbs used for the treatment of hypertension and their mechanism of action. *Current hypertension reports*. 2017; 19(9):77.

JDDT